Therapeutic potential of targeting the oncogenic SHP2 phosphatase

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6594-6609

  Zeng, Li Fan ^a   Zhang, Ruo Yu ^a   Yu, Zhi Hong ^a   Li, Sijiu ^a   Wu, Li ^a   Gunawan, Andrea M ^a   Lane, Brandon S ^a   Mali, Raghuveer S ^a   Li, Xingjun ^a   Chan, Rebecca J ^a   Kapur, Reuben ^a   Wells, Clark D ^a   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(9H FLUOREN 9 YL)METHYL(3 ETHYNYLPHENYL)CARBAMATE; 2 (3 AMINOPHENYL) 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 (2 CARBOXYACETAMIDO)PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 (3 CARBOXYPROPANAMIDO)PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 (4 CARBOXYBUTANAMIDO)PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 (CARBOXYFORMAMIDO)PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 (5 BROMOINDOLIN 1 YL) 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 (BENZO[D]THIAZOL 2 YLAMINO) 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [(1,1 BIPHENYL) 4 YLAMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [(1,1' BIPHENYL) 3 YLAMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [(3 CHLOROPHENYL)AMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [(6 BROMOBENZO[D]THIAZOL 2 YL)AMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [[2 (1H BENZO[D]IMIDAZOL 2 YL)PHENYL]AMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [[3 (BENZYLOXY)PHENYL]AMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [[4 (1H IMIDAZOL 1 YL)PHENYL]AMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 2 [3 [2 [[4 (BENZYLOXY) 3 CHLOROPHENYL]AMINO] 2 OXOACETAMIDO]PHENYL] 6 HYDROXY 3IODO 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; 6 HYDROXY 3 IODO 1 METHYL 2 [3 [2 OXO 2 [[4 (THIOPHEN 3 YL)PHENYL]AMINO]ACETAMIDO]PHENYL] 1H INDOLE 5 CARBOXYLIC ACID; 6 HYDROXY 3 IODO 2 [3 [2 [(4 IODOPHENYL)AMINO] 2 OXOACETAMIDO]PHENYL] 1 METHYL 1H INDOLE 5 CARBOXYLIC ACID; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; HYDROXYINDOLE CARBOXYLIC ACID; METHYL 2 (3 AMINOPHENYL) 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLATE; METHYL 2 [3 [[[(9H FLUOREN 9 YL)METHOXY]CARBONYL]AMINO]PHENYL] 6 HYDROXY 3 IODO 1 METHYL 1H INDOLE 5 CARBOXYLATE; METHYL 5 [[3 [[[(9H FLUOREN 9 YL)METHOXY]CARBONYL]AMINO]PHENYL]ETHYNYL] 4 (DIMETHYLAMINO) 2 HYDROXYBENZOATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; INDOLE DERIVATIVE; MOLECULAR LIBRARY;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; LUNG CANCER; PROTEIN TARGETING; CHEMISTRY; DRUG SCREENING; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84906080682     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5006176     Document Type: Article

References (70)

1. Hunter, T. Tyrosine phosphorylation: thirty years and counting Curr. Opin. Cell Biol. 2009, 21, 140-146
2. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease Nature Rev. Mol. Cell Biol. 2006, 7, 833-846
3. Zhang, Z.-Y. Protein tyrosine phosphatases: prospects for therapeutics Curr. Opin. Chem. Biol. 2001, 5, 416-423
4. Julien, S. G.; Dubé, N.; Hardy, S.; Tremblay, M. L. Inside the human cancer tyrosine phosphatome Nature Rev. Cancer 2011, 11, 35-49
5. Krause, D. S.; Van Etten, R. A. Tyrosine kinases as targets for cancer therapy N. Engl. J. Med. 2005, 353, 172-187
6. Ventura, J. J.; Nebreda, A. R. Protein kinases and phosphatases as therapeutic targets in cancer Clin. Transl. Oncol. 2006, 8, 153-160
7. Cohen, P.; Alessi, D. R. Kinase Drug Discovery-What's Next in the Field? ACS Chem. Biol. 2013, 8, 96-104
8. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S. H.; Giovanella, B. C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 1997, 275, 1943-1947
9. Wang, Z.; Shen, D.; Parsons, D. W.; Bardelli, A.; Sager, J.; Szabo, S.; Ptak, J.; Silliman, N.; Peters, B. A.; van der Heijden, M. S.; Parmigiani, G.; Yan, H.; Wang, T. L.; Riggins, G.; Powell, S. M.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutational analysis of the tyrosine phosphatome in colorectal cancers Science 2004, 304, 1164-1166
10. Neel, B. G.; Gu, H. H.; Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem. Sci. 2003, 28, 284-293
11. Chan, R. J.; Feng, G. S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase Blood 2007, 109, 862-867
12. Grossmann, K. S.; Rosário, M.; Birchmeier, C.; Birchmeier, W. The tyrosine phosphatase Shp2 in development and cancer Adv. Cancer Res. 2010, 106, 53-89
13. Tartaglia, M.; Mehler, E. L.; Goldberg, R.; Zampino, G.; Brunner, H. G.; Kremer, H.; van der Burgt, I.; Crosby, A. H.; Ion, A.; Jeffery, S.; Kalidas, K.; Patton, M. A.; Kucherlapati, R. S.; Gelb, B. D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nature Genet. 2001, 29, 465-468
14. Tartaglia, M.; Gelb, B. D. Noonan syndrome and related disorders: genetics and pathogenesis Annu. Rev. Genomics Hum. Genet. 2005, 6, 45-68
15. Tartaglia, M.; Niemeyer, C. M.; Fragale, A.; Song, X.; Buechner, J.; Jung, A.; Hahlen, K.; Hasle, H.; Licht, J. D.; Gelb, B. D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia Nature Genet. 2003, 34, 148-150
16. Tartaglia, M.; Martinelli, S.; Cazzaniga, G.; Cordeddu, V.; Iavarone, I.; Spinelli, M.; Palmi, C.; Carta, C.; Pession, A.; Arico, M.; Masera, G.; Basso, G.; Sorcini, M.; Gelb, B. D.; Biondi, A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia Blood 2004, 104, 307-313
17. Loh, M. L.; Vattikuti, S.; Schubbert, S.; Reynolds, M. G.; Carlson, E.; Lieuw, K. H.; Cheng, J. W.; Lee, C. M.; Stokoe, D.; Bonifas, J. M.; Curtiss, N. P.; Gotlib, J.; Meshinchi, S.; Le Beau, M. M.; Emanuel, P. D.; Shannon, K. M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis Blood 2004, 103, 2325-2331
18. Loh, M. L.; Reynolds, M. G.; Vattikuti, S.; Gerbing, R. B.; Alonzo, T. A.; Carlson, E.; Cheng, J. W.; Lee, C. M.; Lange, B. J.; Meshinchi, S.; Children's Cancer Group PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group Leukemia 2004, 18, 1831-1834
19. Kratz, C. P.; Niemeyer, C. M.; Castleberry, R. P.; Cetin, M.; Bergsträsser, E.; Emanuel, P. D.; Hasle, H.; Kardos, G.; Klein, C.; Kojima, S.; Stary, J.; Trebo, M.; Zecca, M.; Gelb, B. D.; Tartaglia, M.; Loh, M. L. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease Blood 2005, 106, 2183-2185
20. Bentires-Alj, M.; Paez, J. G.; David, F. S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J. M.; Richardson, A.; Bardelli, A.; Sugarbaker, D. J.; Richards, W. G.; Du, J.; Girard, L.; Minna, J. D.; Loh, M. L.; Fisher, D. E.; Velculescu, V. E.; Vogelstein, B.; Meyerson, M.; Sellers, W. R.; Neel, B. G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia Cancer Res. 2004, 64, 8816-8820
21. Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors Oncogene 2008, 27, 3508-3515
22. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008, 455, 1061-1068
23. Taylor, B. S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B. S.; Arora, V. K.; Kaushik, P.; Cerami, E.; Reva, B.; Antipin, Y.; Mitsiades, N.; Landers, T.; Dolgalev, I.; Major, J. E.; Wilson, M.; Socci, N. D.; Lash, A. E.; Heguy, A.; Eastham, J. A.; Scher, H. I.; Reuter, V. E.; Scardino, P. T.; Sander, C.; Sawyers, C. L.; Gerald, W. L. Integrative genomic profiling of human prostate cancer Cancer Cell 2010, 18, 11-22
24. Brennan, C. W.; Verhaak, R. G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S. R.; Zheng, S.; Chakravarty, D.; Sanborn, J. Z.; Berman, S. H.; Beroukhim, R.; Bernard, B.; Wu, C. J.; Genovese, G.; Shmulevich, I.; Barnholtz-Sloan, J.; Zou, L.; Vegesna, R.; Shukla, S. A.; Ciriello, G.; Yung, W. K.; Zhang, W.; Sougnez, C.; Mikkelsen, T.; Aldape, K.; Bigner, D. D.; Van Meir, E. G.; Prados, M.; Sloan, A.; Black, K. L.; Eschbacher, J.; Finocchiaro, G.; Friedman, W.; Andrews, D. W.; Guha, A.; Iacocca, M.; O'Neill, B. P.; Foltz, G.; Myers, J.; Weisenberger, D. J.; Penny, R.; Kucherlapati, R.; Perou, C. M.; Hayes, D. N.; Gibbs, R.; Marra, M.; Mills, G. B.; Lander, E.; Spellman, P.; Wilson, R.; Sander, C.; Weinstein, J.; Meyerson, M.; Gabriel, S.; Laird, P. W.; Haussler, D.; Getz, G.; Chin, L.; TCGA Research Network The somatic genomic landscape of glioblastoma Cell 2013, 155, 462-477
25. Aceto, N.; Sausgruber, N.; Brinkhaus, H.; Gaidatzis, D.; Martiny-Baron, G.; Mazzarol, G.; Confalonieri, S.; Quarto, M.; Hu, G.; Balwierz, P. J.; Pachkov, M.; Elledge, S. J.; van Nimwegen, E.; Stadler, M. B.; Bentires-Alj, M. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop Nature Med. 2012, 18, 529-537
26. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L.; DePinho, R. A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 2007, 318, 287-290
27. Noren-Muller, A.; Reis-Correa, I.; Prinz, H.; Rosenbaum, C.; Saxena, K.; Schwalbe, H. J.; Vestweber, D.; Cagna, G.; Schunk, S.; Schwarz, O.; Schiewe, H.; Waldmann, H. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 10606-10611
28. Chen, L. W.; Sung, S. S.; Yip, M. L. R.; Lawrence, H. R.; Ren, Y.; Guida, W. C.; Sebti, S. M.; Lawrence, N. J.; Wu, J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor Mol. Pharmacol. 2006, 70, 562-570
29. Dawson, M. I.; Xia, Z.; Jiang, T.; Ye, M.; Fontana, J. A.; Farhana, L.; Patel, B.; Xue, L. P.; Bhuiyan, M.; Pellicciari, R.; Macchiarulo, A.; Nuti, R.; Zhang, X. K.; Han, Y. H.; Tautz, L.; Hobbs, P. D.; Jong, L.; Waleh, N.; Chao, W. R.; Feng, G. S.; Pang, Y.; Su, Y. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity J. Med. Chem. 2008, 51, 5650-5662
30. Geronikaki, A.; Eleftheriou, P.; Vicini, P.; Alam, I.; Dixit, A.; Saxena, A. K. 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action J. Med. Chem. 2008, 51, 5221-5228
31. Lawrence, H. R.; Pireddu, R.; Chen, L. W.; Luo, Y. T.; Sung, S. S.; Szymanski, A. M.; Yip, M. L. R.; Guida, W. C.; Sebti, S. M.; Wu, J.; Lawrence, N. J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds J. Med. Chem. 2008, 51, 4948-4956
32. Hellmuth, K.; Grosskopf, S.; Lum, C. T.; Wurtele, M.; Roder, N.; Kries, J. P. V.; Rosario, M.; Rademann, J.; Birchmeier, W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7275-7280
33. Yu, W. M.; Guvench, O.; MacKerell, A. D.; Qu, C. K. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay J. Med. Chem. 2008, 51, 7396-7404
34. Wu, D.; Pang, Y.; Ke, Y.; Yu, J.; He, Z.; Tautz, L.; Mustelin, T.; Ding, S.; Huang, Z.; Feng, G.-S. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase PLoS One 2009, 4, e4914
35. Zhang, X.; He, Y.; Liu, S.; Yu, Z.; Jiang, Z.-X.; Yang, Z.; Dong, Y.; Nabinger, S. C.; Wu, L.; Gunawan, A. M.; Wang, L.; Chan, R. J.; Zhang, Z.-Y. Salicylic acid-based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) J. Med. Chem. 2010, 53, 2482-2493
36. Liu, D.; Kong, G.; Chen, Q. C.; Wang, G.; Li, J.; Xu, Y.; Lin, T.; Tian, Y.; Zhang, X.; Yao, X.; Feng, G.; Lu, Z.; Chen, H. Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2 Bioorg. Med. Chem. Lett. 2011, 21, 6833-6837
37. Scott, L. M.; Chen, L.; Daniel, K. G.; Brooks, W. H.; Guida, W. C.; Lawrence, H. R.; Sebti, S. M.; Lawrence, N. J.; Wu, J. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs Bioorg. Bioorg. Med. Chem. Lett. 2011, 21, 730-733
38. Yu, Z.-H.; Chen, L.; Wu, L.; Liu, S.; Wang, L.; Zhang, Z.-Y. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening Bioorg. Med. Chem. Lett. 2011, 21, 4238-4242
39. Liu, S.; Yu, Z.; Yu, X.; Huang, S.-X.; Luo, Y.; Wu, L.; Shen, W.; Yang, Z.; Wang, L.; Gunawan, A. M.; Chan, R. J.; Shen, B.; Zhang, Z.-Y. SHP2 is a target of the immunosuppressant tautomycetin Chem. Biol. 2011, 18, 101-110
40. Liu, W.; Yu, B.; Xu, G.; Xu, W. R.; Loh, M. L.; Tang, L. D.; Qu, C. K. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11) J. Med. Chem. 2013, 56, 7212-7221
41. Yu, B.; Liu, W.; Yu, W. M.; Loh, M. L.; Alter, S.; Guvench, O.; Mackerell, A. D., Jr.; Tang, L. D.; Qu, C. K. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies Mol. Cancer Ther. 2013, 12, 1738-1748
42. Puius, Y. A.; Zhao, Y.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 13420-13425
43. Zhang, Z.-Y. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development Annu. Rev. Pharmacol. Toxicol. 2002, 42, 209-234
44. He, R.; Zeng, L.-F.; He, Y.; Zhang, S.; Zhang, Z.-Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases FEBS J. 2013, 280, 731-750
45. Yu, X.; Sun, J.-P.; He, Y.; Guo, X.-L.; Liu, S.; Zhou, B.; Hudmon, A.; Zhang, Z.-Y. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 19767-19772
46. Zhou, B.; He, Y.; Zhang, X.; Xu, J.; Luo, Y.; Wang, Y.; Franzblau, S. G.; Yang, Z.; Chan, R. J.; Liu, Y.; Zheng, J.; Zhang, Z.-Y. Targeting Mycobacterium Protein Tyrosine Phosphatase B for Anti-Tuberculosis Agents Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 4573-4578
47. Zeng, L.-F.; Xu, J.; He, Y.; He, R.; Wu, L.; Gunawan, A. M.; Zhang, Z.-Y. A Facile Hydroxyindole Carboxylic Acid-Based Focused Library Approach for Potent and Selective Inhibitors of Mycobacterium Protein Tyrosine Phosphatase B ChemMedChem 2013, 8, 904-908
48. He, Y.; Xu, J.; Yu, Z.-H.; Gunawan, A. M.; Wu, L.; Wang, L.; Zhang, Z.-Y. Discovery and Evaluation of Novel Inhibitors of Mycobacterium Protein Tyrosine Phosphatase B from the 6-Hydroxy-Benzofuran-5-Carboxylic Acid Scaffold J. Med. Chem. 2013, 56, 832-842
49. He, Y.; Liu, S.; Menon, A.; Stanford, S.; Oppong, E.; Gunawan, A. M.; Wu, L.; Wu, D. J.; Barrios, A. M.; Bottini, N.; Cato, A. C.; Zhang, Z.-Y. A potent and selective small molecular inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases J. Med. Chem. 2013, 56, 4990-5008
50. Mali, R. S.; Ma, P.; Zeng, L.-F.; Martin, H.; Ramdas, B.; He, Y.; Sims, E.; Gosh, J.; Nabinger, S.; Li, S.; Munugalavadla, V.; Craig, A. W.; Bunting, K. D.; Feng, G.-S.; Chan, R. J.; Zhang, Z.-Y.; Kapur, R. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT Blood 2012, 120, 2669-2678
51. Xu, J.; Zeng, L.-F.; Shen, W.; Turchi, J. J.; Zhang, Z.-Y. Targeting SHP2 for EGFR inhibitor resistant non small cell lung carcinoma Biochem. Biophys. Res. Commun. 2013, 439, 586-590
52. Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Muller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome Cell 2009, 136, 352-363
53. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 2004, 305, 1163-1167
54. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 2, e73
55. Dance, M.; Montagner, A.; Salles, J. P.; Yart, A.; Raynal, P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway Cell Signalling 2008, 20, 453-459
56. Ren, Y.; Meng, S.; Mei, L.; Zhao, Z. J.; Jove, R.; Wu, J. (2004) Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor J. Biol. Chem. 2004, 279, 8497-8505
57. Yamauchi, K.; Milarski, K. L.; Saltiel, A. R.; Pessin, J. E. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 664-668
58. Marquardt, B.; Frith, D.; Stabel, S. Signalling from TPA to MAP kinase requires protein kinase C, raf and MEK: reconstitution of the signalling pathway in vitro Oncogene 1994, 9, 3213-3218
59. Ueda, Y.; Hirai, S.; Osada, S.; Suzuki, A.; Mizuno, K.; Ohno, S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent of Raf J. Biol. Chem. 1996, 271, 23512-23519
60. Weigelt, B.; Lo, A. T.; Park, C. C.; Gray, J. W.; Bissell, M. J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment Breast Cancer Res. Treat. 2010, 122, 35-43
61. Muthuswamy, S. K.; Xue, B. Cell polarity as a regulator of cancer cell behavior plasticity Annu. Rev. Cell Dev. Biol. 2012, 28, 599-625
62. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; Kawano, K.; Hanada, M.; Kurata, A.; Takeda, M.; Muhammad Tunio, G.; Matsuzawa, Y.; Kanakura, Y.; Shinomura, Y.; Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 1998, 279, 577-580
63. Longley, B. J.; Reguera, M. J.; Ma, Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy Leuk. Res. 2001, 25, 571-576
64. Minor, W.; Cymborowski, M.; Otwinowski, Z.; Chruszcz, M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes Acta. Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 859-866
65. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025
66. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system: a new software suite for macro-molecular structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921
67. Brünger, A. T. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures Nature 1992, 355, 472-475
68. Emsley, P.; Lohkamp, B.; Scott, W.; Cowtan, K. Features and Development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
69. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility J. Comput. Chem. 2009, 30, 2785-2791
70. Sanner, M. F. Python: A programming language for software integration and development Journal Mol. Graphics Modell. 1999, 17, 57-61